Written by:
Reviewed by:
Breast cancer immunotherapy (IT) represents a groundbreaking advancement in oncology, encompassing various innovative approaches to breast cancer treatment. Breast cancer (BC, BCa) is one of the most common malignant tumors globally [1], but here's the thing – it's been considered an immunologically "cold" tumor with way less T-cell infiltration and lower mutational load compared to other "hot" solid tumors like non-small cell lung carcinoma and melanoma. This made it harder to treat with affecting the immune system drugs for a long time.
The most immune response-stimulating subtype in the breast cancer statistics now is triple negative breast cancer (TNBC) [2]. It demonstrates high PD-L1 expression, lots of tumor-infiltrating lymphocytes (TIL), genomic instability and high mutation rates. These are pretty good factors – in the KEYNOTE-522 study, adding boosting the immune system medications to chemotherapy raised complete response rates, improved overall survival, and event-free survival [3]. The implementation of immunotherapy for breast cancer triple-negative form is the most responsive to this approach. Immunotherapy and triple negative breast cancer work by using the immune system to detect and destroy cancer cells, overcoming their ability "to hide" from the body's defenses. It solves a critical problem – the tumor`s blocking of T-cell activity through checkpoint molecules and hiding the surface markers, becoming invisible to human immunity.
The German specialists gained real experience with hard cases – recurring, metastatic, and triple-negative breast cancers (TNBC). With customized protocols and individually-made vaccines, they basically mobilize the body’s immune system against tumor cells to improve survival and quality of life (QoL) for patients. The Nobel Prize in Physiology or Medicine in 2011 was awarded for the discovery of the key principles of immune activation [4], which laid the foundation for one of the types of modern treatment and became a breast cancer immunotherapy breakthrough, but we will talk about this in more detail below.
Before starting to talk about breast cancer and immunotherapy, it is worth understanding the types of mammary gland tumors. Classification of BC is divided into certain histological and molecular types. The most common histological types are ductal and lobular BC. Immunotherapy for lobular breast cancer is no different from treatment for ductal one. Breast cancer immunotherapy indications depend on molecular type, one of which is triple-negative breast cancer (TNBC).
Immunotherapy is a promising method of treating TNBC, in particular its aggressive metaplastic histological subtype. The main tasks of immunotherapy for metaplastic breast cancer for early and metastatic triple negative breast cancer are as follows:
In the early stages, with large resectable tumors, the doctor may prescribe metaplastic breast cancer immunotherapy (IT) before surgery, in combination with chemotherapy. Chemo and immunotherapy for breast cancer help to reduce the size of the tumor and make the operation easier: for example, to resect the organ instead of removing it completely. After the operation, the patient continues to receive adjuvant treatment. Immunotherapy for triple-negative breast cancer after surgery prevents relapses by enhancing the body’s immune system and suppressing the remaining sporadic tumor cells.
If doctors do not perform surgery to remove a tumor, then immunotherapy is used to control triple negative breast cancer. It inhibits the further tumor growth and progression of metastatic breast cancer throughout the body. This option is used in the advanced triple negative breast cancer stages, with active metastasizing, or if the woman refuses to treat breast cancer (BC) surgically for any reason. Stage 3 breast cancer immunotherapy (IT) is combined with chemotherapy, hormone therapy, and radiation therapy. This is possible due to its excellent tolerability.
Immunotherapy for triple-negative breast cancer – is a modern treatment strategy that uses and enhances the body's natural ability to recognize and destroy cancer cells. It acts on different parts of the immune system. Sometimes these are factory-made immune response-modifying drugs; sometimes, these are drugs that are manufactured individually, using the patient's immune cells. Doctors in breast cancer immunotherapy clinics use three main groups of immune system affecting drugs (some for TNBC and some for hormone receptor positive breast cancer (HR+, HER2+), including metastatic breast cancer (mBC)), these are:
Immune checkpoint inhibitors (ICI) are drugs for targeted treatment that disrupt tumor cells’ ability to hide from the attacks of the immune system. Normally, a woman's immune system recognizes and destroys the very first tumor cells in the mammary gland, preventing tumor development. Unfortunately, a tumor can hide signs of malignancy and resemble healthy tissue. This is recognized and removed by immune checkpoint inhibitors (ICI). The pharmacological group includes drugs against various tumor molecules: PD-1 or PD-L1 inhibitors and CTLA-4 inhibitors (ICB). Before starting to treat breast cancer (BCa) with immune response-modifying drugs, doctors determine the initial level of PD-1 in tumor cells: to achieve a good result, and it must be high.
Today, immune checkpoint inhibitors as an immunotherapy for inflammatory breast cancer is not included in standard treatment protocols, because clinical data on its effectiveness in this subtype remain limited.
Dendritic cell vaccines stimulate natural specific immunity, a targeted immune response. This is a strictly individual type of hormone receptor positive and triple negative breast cancer treatment; doctors use tumor components and the patient's leukocytes to make a vaccine. In laboratory conditions, leukocytes "get acquainted" with the surface antigens (NeoAg) of a tumor. Such leukocytes, T-cells, are called dendritic cells, and after being infused into the blood, they become able to find the tumor and metastases. Dendritic cells help all the other immunocompetent cells detect a tumor: some of such cells directly destroy malignant foci, and others form a long-term immune response and immunological memory in order to prevent a relapse. The immune system's response is transformative – once activated, it develops and maintains a lifelong memory against the specific tumor cells.
Adoptive cell therapy (ACT) is a technologically more complex type of changing a patient's T-cells, leukocytes. After such a modification, T-cells can successfully find and attack hormone receptor positive and triple negative breast cancer foci, regardless of their localization. CAR T-cell immunotherapy for breast cancer involves the genetic modification of white blood cells: a special receptor is added to them and makes them able to bind to tumor cells. Information about the new receptor is fixed in the genome so that it is reproduced in new generations of leukocytes to fight metastatic breast cancer (mBC) longer.
Nanotechnology is also being used to fight early breast cancer and metastatic breast cancer. Nanoparticles deliver imaging compounds (at the diagnostic stage), phototherapy compounds, or drugs (at the treatment stage) to breast cancer cells.
For stage 4 TNBC patients who have received multiple prior chemotherapy lines, the antigen landscape at the time of DC vaccination may differ substantially from what was present at initial diagnosis. TNBC tumor cell populations evolve under the selective pressure of prior treatment, meaning that a vaccine loaded from tissue obtained before prior chemotherapy may not accurately reflect the antigens the immune system needs to target now.
Booking Health's pre-treatment case review assesses the case and schedules a liquid biopsy before protocol is confirmed, because the personalization that makes DC therapy effective depends entirely on the currency of the antigen data it is built from.
CHECK IF A BETTER SOLUTION EXISTS FOR YOUTNBC – is a subtype of the disease characterized by the absence or low expression of three receptors: estrogen (ER), progesterone (PR), and human epidermal growth factor receptor 2 (HER2). This tumor has no specific targets. Therefore traditional hormone therapy or HER2-targeting agents are ineffective [7]. TNBC has a high ability to invade internal organs (such as the brain, lungs or liver) and rapid metastasis. There is a significant connection of this subtype with BRCA1 gene mutation (about 35% of patients) [8].
Despite its aggressiveness, this subtype is the most immunogenic one, which creates a unique biological synergy between triple negative breast cancer and immunotherapy due to the high level of tumor-infiltrating lymphocytes (TILs) and PD-L1 expression. But it all depends on the stage of the disease, because the immunotherapy for early stage breast cancer works better, when it is not yet exhausted by previous intensive treatment.
Immunotherapy for breast cancer stage 1 is not used often. This is more suitable for stage 2 and higher. Immunotherapy for breast cancer stage 2 is aimed at preventing disease recurrence. Immunotherapy can be conducted both before (neoadjuvant mode) and after (adjuvant mode) surgery:
For large tumors that have spread to nearby tissues or lymph nodes, immunotherapy helps turn an inoperable condition into operable:
At this stage, disease has already spread to distant organs, so doctors often incorporate advanced systemic approaches. Immunotherapy for metastatic breast cancer treatment at this stage is aimed at prolonging life and controlling symptoms. But there are certain nuances:
It is also worth mentioning TNBC. It is a clinical morphological subtype of mammary carcinoma characterized by the simultaneous expression of three key biomarkers: estrogen receptors (ER), progesterone receptors (PR) and amplification or overexpression of the human epidermal growth factor receptor type 2 (HER2). Breast cancer treatment immunotherapy is generally not the primary focus here, as the main treatment in such cases is targeted therapy aimed at blocking HER2 receptors. It is also prescribed long-term hormone therapy to suppress the effect of estrogen and progesterone on tumor cells. So, as you understand, immunotherapy for triple positive breast cancer is not a first-line treatment.
Therefore, due to the biological heterogeneity of the tumors, not every patient is a suitable candidate for such treatment. Even though immunotherapy for breast cancer side effects can be controlled, sometimes clinical challenges require careful management. Ultimately, a personalized approach is the only way to achieve stable remission and improve the QoL, especially for those undergoing immunotherapy for breast cancer stage 4.
The statement that immunotherapy for early stage breast cancer works better "when it is not yet exhausted by previous intensive treatment" carries a practical implication for how quickly post-surgical adjuvant vaccination should be organized. Immune function is at its most responsive in the weeks immediately following surgery, before adjuvant chemotherapy cycles begin their cumulative suppressive effect on T-cell populations.
For international patients, that window is narrowed by every week spent on administrative preparation.
Booking Health prioritizes the organizational timeline for adjuvant cases — document preparation, clinic scheduling, and travel logistics are compressed into parallel rather than sequential steps — so the patient's immune system at vaccination is as intact as the clinical window allows.
Immune checkpoint inhibitors (PD-1/PD-L1 inhibitors, CTLA-4 inhibitors) are given by injections. They are dripped through a vein in an outpatient facility under medical supervision. The drug is administered intravenously once every 3-6 weeks, depending on the general therapeutic regimen. Immune checkpoint inhibitors are well tolerated and have only occasional minor side effects (e.g., fatigue, loss of appetite, nausea, diarrhea). It is a suitable option for immunotherapy for breast cancer, including metastatic triple-negative breast cancer (mTNBC).
Dendritic cell therapy represents a sophisticated yet remarkably straightforward personalized immune system-stimulating treatment approach that has been made possible by Ralph Steinman, who was awarded the 2011 Nobel Prize in Medicine for his discovery of dendritic cells.
The entire process consists of just two outpatient visits with minimal disruption to daily life. During the first visit, specialists conduct:
After just seven days, during which the personalized dendritic cell vaccine is created, patients return for a single day of treatment that includes the vaccine injection and any necessary supportive care. This efficient, patient-friendly approach makes it particularly attractive for those seeking effective treatment with minimal hospital time.
To provide deeper insight into these vaccines, we spoke with Professor Frank Gansauge, a leading expert in dendritic cell therapy with over 22 years of experience. As the head of LDG Laboratories, which has successfully performed more than 2,500 dendritic cell procedures, Prof. Gansauge explains the innovative nature of this immune system-stimulating treatment and its remarkable effectiveness for early and metastatic breast cancer (mBC). His clinic's approach aims not only to kill cancer cells but also to maintain patients' quality of life throughout the therapy process.
VIDEO
Dendritic Cell Therapy
Adoptive cell therapy (CAR T-cell therapy) requires inpatient treatment. Hospital admission is obligatory, as patients receive high-dose chemotherapy before the breast cancer immunotherapy infusion of modified CAR T-cells. Chemotherapy temporarily reduces the level of a woman's leukocytes, so the injected modified CAR T-cells multiply more actively and provide stable anti-tumor immune system response faster. The laboratory stage of CAR T-cells creation can take up to 3 weeks, so the patient visits the clinic twice: for blood donation and directly for treatment boosting the immune system.
All costs and survival rates are based on Booking Health data and vary depending on disease type, stage, patient condition, and their immune response.
| Characteristic | Checkpoint inhibitors | Dendritic Cell Vaccines | CAR T-Cell Therapy |
|---|---|---|---|
| Treatment approach | Factory-made drugs (PD-1/PD-L1, CTLA-4 inhibitors) | Personalized vaccine using patient's immune cells | Genetically modified patient's immune cells |
| Treatment setting | Outpatient | Outpatient | Inpatient (hospital admission required) |
| Number of visits | Multiple (every 3-6 weeks) | Two visits total | Two visits (blood donation + treatment) |
| Treatment duration | Ongoing course (3-6 weeks between doses) | Single procedure after 7-day vaccine creation | Single intervention after 3-week cell modification |
| Preparation needed | PD-L1 testing (must be high) | Blood collection for cancer vaccine | High-dose chemotherapy before infusion |
| Side effects | Occasional minor: fatigue, appetite loss, nausea, diarrhea | Very mild, allows normal daily activities | Related to preparatory chemotherapy |
| Best suited for | PD-L1+ tumors, combination with chemo | Early-stage breast cancer, locally advanced breast cancer, stage 4 exhausted patients, personalized approach to immune cells training | Advanced breast cancer cases needing intensive intervention |
| Response rate | Up to 45% | Up to 90% | Up to 40% |
| Cost (EUR) | 375,000-420,000 (full course) | 20,000-38,000 | 450,000-550,000 |
| Key advantage | Proven in clinical studies, standard option for immune system activation | Best tolerability, lifelong immune response, highest response rate | Ability to destroy cancer cells regardless of location |
| Treatment principle | Blocks tumor's ability to hide from immune system | Trains immune system to recognize tumor cells | Adds special receptors to find and attack cancer cells |
The "Preparation needed" row contains the most consequential pre-treatment requirement for each modality: PD-L1 testing must confirm high expression before checkpoint inhibitors are prescribed; blood collection and current antigen material must be available for DC vaccine manufacturing; high-dose chemotherapy eligibility must be confirmed before CAR T-cell infusion. None of these prerequisites should be discovered at the clinic on the day of the first appointment — each needs to be confirmed from the incoming record before the visit is scheduled.
Booking Health's pre-treatment review maps each patient's current molecular profile and health status against the preparation requirements in this table.
FIND THE RIGHT SPECIALIST FOR MY CASEImmunotherapy for TNBC breast cancer has such benefits:
Drugs affecting the immune system are easy to use. Unlike chemotherapy, they do not have to be given in long courses, spending weeks in hospital. Most breast cancer immunotherapy medications are given once every 3 to 6 weeks. In the case of dendritic cell therapy, a single procedure is sufficient for the induction of durable antitumor immunity.
The effectiveness of immunotherapy in triple negative breast cancer varies depending on the chosen method and the mechanism of its action on the immune system. Below are statistics of three leading treatment strategies – dendritic cell therapy, checkpoint inhibitors, and CAR T-cell therapy.
*Booking Health data. Survival rates vary widely depending on the type of tumor, the patient's condition, and specific circumstances.
**Booking Health data. Response rate is the number of patients who show improvement after treatment.
| Treatment | 2-Year Survival Rate* | Response Rate** | Method efficiency | Frequency of use |
|---|---|---|---|---|
| Dendritic cell therapy | up to 85% | up to 90% | Effective at any stage of the disease (it is often used as an immunotherapy in metastatic breast cancer) | It is often used as a universal component of treatment |
| Checkpoint inhibitors | up to 45% | up to 45% | The greatest effectiveness is demonstrated in the early stages of the disease | The use is limited by the presence of specific biomarkers on the tumor |
| CAR T-cell therapy | up to 50% | up to 40% | It is indicated mostly for advanced disease | It is also used quite often |
The question of the breast cancer immunotherapy cost in Germany and other leading medical centers in the world does not have a unified answer, since the cost is determined individually for each patient. The final amount of expenses is dynamic and depends on a set of key factors:
To compare the financial availability of modern treatment methods, we have collected up-to-date data on the cost of immunotherapy for triple negative breast cancer and other disease subtypes in the world's leading medical centres. The summary table below shows the price differences for the main immunotherapeutic drugs:
| Treatment | Cost in Germany | Cost in Great Britain | Cost in USA | Cost in Australia |
|---|---|---|---|---|
| Dendritic cell therapy | €20,000 – €38,000 | Not available | €100,000 – €150,000 | Not available |
| Checkpoint inhibitors | €375,000 – €420,000 for the full course | €400,000 – €500,000 for the full course | €600,000 – €1,000,000 for the full course | €400,000 – €600,000 for the full course |
| CAR T-cell therapy | €450,000 – €550,000 | Not available | $500,000 – $750,000 | $500,000 – $600,000 |
In conclusion, it is important to understand that in modern oncology there is no universal fixed cost of immunotherapy for breast cancer. It is a program formed only after a thorough examination, since each clinical case requires a personalized approach.
For Magdalena Ivanova, hope came unexpectedly from dendritic cell therapy at a German clinic. As a stage 4 of the disease patient with bone metastases she had undergone years of conventional treatment in Bulgaria – eight years of monthly hospital visits, intense chemotherapy sessions and a long recovery from radical mastectomy – before finally considering the potential of immunotherapy for stage 4 breast cancer.
It was then that her children began researching new cancer treatments worldwide. They found out about LDG Laboratories in Berg, Germany, through Booking Health, which provided personalized breast cancer immunotherapy with dendritic cells. This immune system boosting treatment surprised Magdalena at first not with the effectiveness, but with tolerability: she did not suffer from severe side effects usual for systemic medications.
The treatment process was also simple and did not require any preparation. Healthcare specialists took about 150ml of Magdalena’s blood, created a personalized vaccine in the laboratory and administered it as a simple injection. Under the guidance of an experienced professor at LDG Laboratories, Magdalena received comprehensive care.
Perhaps most striking was the contrast in her quality of life during treatment. Where traditional therapy had once dominated her daily routine with restrictions and side effects, dendritic cell therapy allowed her to maintain her normal lifestyle. Her success story at the German clinic illuminates the possibilities that modern breast cancer immunotherapy offers to advanced breast cancer patients.
Possibly most striking was her poor quality of life during the previous treatment, which Magdalena was afraid of now. Where conventional therapies had limited her daily life with side effects and restrictions, dendritic cell therapy allowed her to live normally again. Her success story at the German clinic highlights the options that modern breast cancer immunotherapy can offer advanced breast cancer patients.
VIDEO
Dendritic Cell Therapy
It is important to understand that triple negative breast cancer immunotherapy is a high-tech direction. In many countries patients are still limited to classical protocols because the development and application of such drugs require complex laboratory conditions and specific certification.
Germany remains a key country where immunotherapy is not just available, but integrated into daily clinical practice. This country has several specialized and comprehensive oncology centers for breast cancer immunotherapy. Each facility uses advanced therapeutic approaches for hormone receptor positive breast cancer (HR+, HER2+) and triple-negative breast cancer care.
LDG Laboratories in Berg has become a world leader in dendritic-cell immunotherapy to activate the immune system and kill cancer cells. And their expertise is particularly useful for patients with advanced breast cancer. The LDG Laboratories' personalized approach to vaccine creation has demonstrated impressive results – particularly in breast cancer patients seeking alternative therapies against tumor cells or additions to conventional therapies.
The University Hospital Frankfurt am Main integrates breast cancer immunotherapy into a comprehensive program to boost the immune response. Their multidisciplinary approach combines immune treatments with surgical techniques and precision radiotherapy using CyberKnife. The hospital's tumor board ensures each patient receives care tailored to their specific condition and peculiarities of breast cancer cells.
At the Clinic of Advanced Biological Medicine in Frankfurt am Main, doctors blend traditional immuno-oncology (IO) with biological therapies, focusing on strengthening the immune system while managing treatment side effects. Their four-decade experience in integrative medicine has helped establish protocols that enhance both survival rates and quality of life.
The Asklepios Hospital Barmbek Hamburg offers state-of-the-art breast cancer immunotherapy treatments. Their medical team of 1,600 professionals serves an impressive patient volume annually, maintaining high standards to treat breast cancer recognized by the German Cancer Society.
For patients seeking complementary approaches, the Hyperthermia Center Hannover combines immunotherapy with innovative hyperthermia treatments that influence sensitivity of breast tumor cells to therapeutic interventions. The facility offers comprehensive outpatient care that can destroy cancer cells and address psychological aspects of breast cancer treatment.
Those five centers address different clinical priorities within breast cancer immunotherapy. Booking Health maps each patient's molecular subtype, metastatic pattern, prior treatment history, and primary clinical objective to the center whose documented capabilities most directly address their situation.
GET A SECOND OPINION FOR MY CASEBefore traveling to Germany for hormone receptor positive breast cancer (HR+, HER2+) or triple-negative breast cancer immunotherapy (TNBC), several important steps need to be completed in your home country. The process begins with collecting and translating your medical records, including diagnosis details, previous treatments, and recent examination results. These documents are essential for German specialists to evaluate your case and determine the most appropriate immunotherapy approach. Initial consultations can often be conducted remotely, allowing you to discuss treatment options with German doctors while still at home.
Many women wonder about the timing of immunotherapy in relation to their current breast cancer treatment. German specialists can provide guidance on whether to complete ongoing treatments before starting immunotherapy or if a combination approach would be more beneficial.
When it comes to breast carcinoma, diagnosis time and precision are crucial. We are a group of doctors and managers with more than 15 years of experience in the field of medical tourism. Our mission is to give patients access to top-level German medicine by providing support that goes beyond standard medical services. Being already exhausted from multiple treatment sessions, having consulted numerous specialists, and having tried various therapeutic interventions, finding the best treatment strategy for your clinical situation can become a challenging task. In such a situation, it is easy to choose a first-hand option or to follow standardized therapeutic protocols with a long list of adverse effects instead of selecting highly specialized innovative treatment options.
Over the years, we have processed more than 100,000 requests from all over the world. Behind each of these numbers is a saved life and an individual story of victory over the disease. Thanks to direct contacts with leading oncological centers in Germany, we eliminate bureaucratic barriers and provide access to treatment that is not available in most countries of the world.
To make an informed choice and get a personalized cancer management plan, which will be tailored to your specific clinical situation, consult medical experts at Booking Health. Being at the forefront of offering the latest medical innovations for already 12 years, Booking Health possesses solid expertise in creating complex cancer management programs in each case. As a reputable company, Booking Health offers personalized breast cancer immunotherapy treatment with direct clinic booking and full support at every stage, from organizational processes to assistance during treatment.
We provide:
Health is an invaluable aspect of our lives. Delegating management of something so fragile yet precious should be done only to experts with proven experience and a reputation. Booking Health is a trustworthy partner who assists you in pursuing stronger health and a better quality of life. Our approach is a combination of advanced German technology and personalized medical support. Contact our medical consultant to learn more about the possibilities of personalized treatment, especially metastatic breast cancer immunotherapy with leading specialists in this field.
Booking Health holds ISO 9001 quality certification, reflecting well-established processes and strict quality control at every stage of the treatment journey — not just at the initial consultation, but throughout.
Yes, today immunotherapy of breast cancer is an approved and highly effective type of treatment that has become a part of German treatment standards.
Undoubtedly, immunotherapy and breast cancer have become a key focus in oncology and one of its most promising directions. This method is integrated into treatment plans, both monotherapy and in combination with traditional methods.
It is a modern method of systemic treatment that activates the body`s own protective resources to identify and destroy malignant cells. Understanding immunotherapy for breast cancer is fundamental for patients seeking novel therapeutic options.
This treatment works by activating the body's own defenses to recognize and destroy malignant cells, overcoming their masking mechanisms. The use of targeted immunotherapy for breast cancer allows blocking of specific tumor proteins, turning it into a visible target for the immune system and providing long-term protection against relapses.
It has been proven that significant results in the fight against breast carcinoma are now achieved through advanced immunotherapy. Germany breast cancer programs provide optimal conditions, access to the most modern clinical protocols, and individual patient support.
New immunotherapy for breast cancer provides systemic activation of antitumor immunity by modulating the interaction between tumor antigens and T-cells. This allows overcoming immunosuppression in the tumor zone, promoting a stable cytotoxic effect on malignant cells and preventing further metastasis.
The modern immunotherapy treatment for breast cancer includes several innovative directions that are selected based on the molecular profile of the tumor. The main methods are immune checkpoint inhibitors, dendritic cell (DC) based vaccines, and CAR T-cell therapy.
Immunotherapy for breast cancer in Germany includes checkpoint inhibitors like PD-1/PD-L1 blockers, individualized dendritic cell vaccines, and CAR T-cell therapy, where your own immune cells are modified. Checkpoint inhibitors are pretty simple – IV infusions every few weeks. More individualized dendritic cell therapy requires two visits.
As breast cancer immunotherapy advances, it is used mainly in triple-negative subtypes. Immunotherapy for stage 1 breast cancer is not often applied. Immunotherapy for stage 2 breast cancer has a higher success rate when added to chemotherapy, both before surgery and after.
The effectiveness of immunotherapy in TNBC in Germany is actually quite good. KEYNOTE-522 reported increased complete response rates and overall survival when an IT medication was added to the chemotherapy. High PD-L1 expression and more tumor-infiltrating lymphocytes (TIL) make triple-negative breast cancer more responsive to immunotherapy than other breast tumor types.
The immunotherapy success rate for breast cancer is constantly growing due to the implementation of combined protocols that achieve a complete pathological response (pCR). Immunotherapy for metastatic breast cancer provides long-term control over the disease even in patients previously considered resistant to treatment.
The use of immunotherapy to treat breast cancer provides long-term relapse-free survival even in cases with a high risk of metastasis. By activating the systemic immune response, this method is able to eliminate residual tumor cells, which significantly brings patients closer to victory over the disease.
The side effects of immunotherapy for breast cancer in Germany are way milder than with chemo. Checkpoint inhibitors might cause fatigue, loss of appetite, nausea, or diarrhea – but these are occasional and minor. Dendritic cell therapy is even gentler, letting patients keep up their normal daily activities. That's why it works well even for stage 4 patients who are already exhausted.
Stage 4 breast cancer immunotherapy demonstrates the ability to transform an aggressive process into a controlled chronic condition, providing long-term stabilization and remission. Although complete elimination of the tumor at this stage is a difficult task, immunotherapy for breast cancer 4th stage significantly extends the life of patients, maintaining a high quality of life.
Doctors perform specific tests to determine the suitability of immunotherapy for breast cancer triple-negative forms. But it requires a confirmed high level of PD-L1 expression in your tumor to ensure that checkpoint inhibitors will effectively trigger the necessary immune response. Then they check the level of tumor-infiltrating lymphocytes (TIL) and the tumor subtype. The best immune system's response is with TNBC. German specialists conduct thorough testing before treatment to determine which immunotherapy type suits your case.
The total expenses for treatment depend on the selected program and the duration of the therapy, which defines the individual immunotherapy for breast cancer. Cost in German clinics also varies considerably according to treatment type. Dendritic cell therapy costs EUR 20,000-38,000. Checkpoint inhibitors are EUR 375,000-420,000 per full course. The most expensive is CAR T-cell therapy at EUR 450,000-550,000. They depend on your disease stage, tumor type, and more. Dendritic cell therapy has the highest response rates.
Several clinics for immunotherapy for breast cancer in Germany offer advanced treatments. LDG Laboratories in Berg specializes in dendritic cell therapy with over 2,500 procedures done. University Hospital Frankfurt am Main combines surgery and CyberKnife with immunotherapy for breast cancer treatment. Such a therapy can also be conducted in Asklepios Hospital Barmbek Hamburg, which has modern facilities. Hyperthermia Center Hannover adds complementary approaches to immunotherapy.
The use of immunotherapy after chemo for breast cancer is a common clinical practice, as chemotherapy helps destroy the tumor structure, making it more vulnerable to immune attack. This approach consolidates the result of treatment and activates immune memory to prevent relapse after completing the main course of cytostatics.
Yes, it is. The immunotherapy vs. chemotherapy breast cancer patients receive are not mutually exclusive alternatives. Checkpoint inhibitors are added to chemo, especially before surgery, to shrink tumors. For more advanced cases, doctors use immunotherapy + hormone therapy + RT. The dendritic cell vaccines may be combined with other treatments. The good tolerability permits such combinations without adding serious side effects.
Booking Health immunotherapy support for breast cancer in Germany includes analysis of medical reports and organization of appointments. They help you choose the right clinic, prepare documents, book consultations with specialists, deal with visas and tickets and assign you a personal coordinator with 24 hours support.
Sources:
01. Ran R, Chen X, Yang J, Xu B. Immunotherapy in breast cancer: current landscape and emerging trends. Exp Hematol Oncol. 2025;14:77. doi:10.1186/s40164-025-00667-y. [DOI]
02. Liying Li, Fan Zhang, Zhenyu Liu, Zhimin Fan. Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome. Cancers (Basel). 2023 Jan 3;15(1):321. doi: 10.3390/cancers15010321. [DOI] [PMC free article]
03. Essalihi A, Bouchra O, Khadiri K, Khadrouf Z, Karkouri M. Immunotherapy for triple-negative breast cancer: current trends and future prospects. J Egypt Natl Canc Inst. 2025;37:51. doi:10.1186/s43046-025-00295-x. [DOI]
04. Roman Volchenkov, Florian Sprater, Petra Vogelsang, Silke Appel. The 2011 Nobel Prize in physiology or medicine. Scand J Immunol. 2012 Jan;75(1):1-4. doi: 10.1111/j.1365-3083.2011.02663.x. [DOI] [PubMed]
05. Debien V, De Caluwé A, Wang X, Piccart-Gebhart M, Tuohy VK, Buisseret L. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer. 2023;9:7. doi:10.1038/s41523-023-00508-3. [DOI]
06. Qian D, Li J, Huang M, Cui Q, Liu X, Sun K. Dendritic cell vaccines in breast cancer: immune modulation and immunotherapy. Biomed Pharmacother. 2023;162:114685. doi:10.1016/j.biopha.2023.114685. [DOI]
07. Palma M. Advancing Breast Cancer Treatment: The Role of Immunotherapy and Cancer Vaccines in Overcoming Therapeutic Challenges. Journals. Vaccines. Volume 13. Issue 4 doi: 10.3390/vaccines13040344. [DOI]
08. Obidiro O, Battogtokh G, O.Akala E. Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. Journals. Pharmaceutics. Volume 15. Issue 7. doi: 10.3390/pharmaceutics15071796. [DOI]
09. Dvir K, Giordano S, Leone JP. Immunotherapy in Breast Cancer. Journals. IJMS. Volume 25. Issue 14. doi: 10.3390/ijms25147517. [DOI]
10. Baumrucker CC, Harris N et al. Intratumoral Immunotherapy in Breast Cancer. Journals. Vaccines. Volume 13. Issue 4. doi: 10.3390/vaccines13040429. [DOI]
11. Hu Yu, Yao Zh, Huang F et al. Immunotherapy: Review of the Existing Evidence and Challenges in Breast Cancer. Journals. Cancers. Volume 15. Issue 3. doi: 10.3390/cancers15030563. [DOI]
Read:
01. Comprehensive Guide to Breast Cancer Treatment: New and Standard Treatment Options
Start Treatment in 48 Hours — Fixed Price
Same Clinic Price — Many More Benefits with Booking Health
| benefit | direct clinic booking | With Booking Health |
|---|---|---|
| Clinic list price | same clinic price | same clinic price |
| Fixed, all‑inclusive estimate (no hidden fees) | ||
| Total savings on travel & logistics (≈ 40 – 70 %) | ||
| Start of treatment within 48 hours | ||
| 10 + years medical‑tourism expertise | ||
| Medical case review by a dedicated medical board | ||
| Personal coordinator 24/7 in your language | ||
| Visa, flights, transfer and accommodation support | ||
| Certified translations & document handling | ||
| Access to innovative methods in Germany | ||
| Pre‑negotiated fixed pricing with top clinics | ||
| Risk of unexpected extra costs | fixed price |
Contact Us
Booking Health guarantees
thanks for your request.
Within 1 working day, a medical advisor will study your request and contact you by phone (German or your local number will be displayed).
This call is free for you.
New Effective Treatments for Stage 4 Cancer: Innovations in Oncology
